BGIM
EW icon

Boussard & Gavaudan Investment Management’s Edwards Lifesciences EW Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,830
Closed -$233K – 33
2014
Q4 		$233K Sell
10,830
-6,156
-36% -$124K 0.15% 14
2014
Q3 		$292K Buy
+16,986
New +$268K 0.17% 13

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Boussard & Gavaudan Investment Management's EW Position: Q1 2015 in Review

Boussard & Gavaudan Investment Management sold out of Edwards Lifesciences (EW) in Q1 2015, closing a stake of 10,830 shares — an estimated $233K sold.

Boussard & Gavaudan Investment Management first reported a position in EW in Q3 2014 and held it in 2 quarters. The position peaked at $292K in Q3 2014. 576 funds tracked by Wall St. Rank hold EW as of Q1 2015.

  • Boussard & Gavaudan Investment Management reported no remaining Edwards Lifesciences position as of Q1 2015 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 10,830 Edwards Lifesciences shares in Q1 2015, an estimated $233K.
  • Boussard & Gavaudan Investment Management first reported a position in Edwards Lifesciences in Q3 2014 and held it in 2 quarters.
  • Boussard & Gavaudan Investment Management's Edwards Lifesciences position peaked at $292K in Q3 2014.
  • 576 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2015.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2015, filed 12 May 2015.